InsiderTrades.com logo
America’s worst nightmare?
From Porter & Company   |   Ad
What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.
Click here to watch this bombshell exposé now.
Cameron Turtle net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Cameron Turtle Biography and Net Worth

Insider of Eidos Therapeutics
Cameron Turtle, DPhil, is the Chief Business Officer of Eidos Therapeutics.
He was a consultant in McKinsey & Company’s Silicon Valley office, where he worked with biotech, pharmaceutical, and medical product companies on strategy for mergers and acquisitions, due diligence, growth and clinical trial strategy, and commercial operations.
Turtle earned his DPhil in Cardiovascular Medicine as a Rhodes Scholar at the University of Oxford and his B.S. in Bioengineering from the University of Washington.

What is Cameron Turtle's net worth?

The estimated net worth of Cameron Turtle is at least $2.45 million as of December 28th, 2020. Dr. Turtle owns 20,068 shares of Eidos Therapeutics stock worth more than $2,452,510 as of May 15th. This net worth estimate does not reflect any other assets that Dr. Turtle may own. Additionally, Dr. Turtle receives an annual salary of $578,400.00 as Insider at Eidos Therapeutics. Learn More about Cameron Turtle's net worth.

How old is Cameron Turtle?

Dr. Turtle is currently 31 years old. There are 6 older executives and no younger executives at Eidos Therapeutics. Learn More on Cameron Turtle's age.

What is Cameron Turtle's salary?

As the Insider of Eidos Therapeutics, Inc., Dr. Turtle earns $578,400.00 per year. Learn More on Cameron Turtle's salary.

How do I contact Cameron Turtle?

The corporate mailing address for Dr. Turtle and other Eidos Therapeutics executives is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. Eidos Therapeutics can also be reached via phone at 415-887-1471 and via email at [email protected]. Learn More on Cameron Turtle's contact information.

Has Cameron Turtle been buying or selling shares of Eidos Therapeutics?

Cameron Turtle has not been actively trading shares of Eidos Therapeutics during the past quarter. Most recently, Cameron Turtle sold 26,294 shares of the business's stock in a transaction on Tuesday, December 15th. The shares were sold at an average price of $111.77, for a transaction totalling $2,938,880.38. Following the completion of the sale, the insider now directly owns 55,072 shares of the company's stock, valued at $6,155,397.44. Learn More on Cameron Turtle's trading history.

Who are Eidos Therapeutics' active insiders?

Eidos Therapeutics' insider roster includes Jonathan Fox (Insider), Uma Sinha (Insider), Cameron Turtle (Insider), and Franco Valle (SVP). Learn More on Eidos Therapeutics' active insiders.

Cameron Turtle Insider Trading History at Eidos Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2020Sell26,294$111.77$2,938,880.3855,072View SEC Filing Icon  
11/11/2020Sell13,410$74.51$999,179.1062,526View SEC Filing Icon  
11/2/2020Sell12,500$70.72$884,000.0075,531View SEC Filing Icon  
8/3/2020Sell10,000$39.94$399,400.0080,531View SEC Filing Icon  
6/4/2019Sell10,000$31.64$316,400.00View SEC Filing Icon  
See Full Table

Cameron Turtle Buying and Selling Activity at Eidos Therapeutics

This chart shows Cameron Turtle's buying and selling at Eidos Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eidos Therapeutics Company Overview

Eidos Therapeutics logo
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Read More

Today's Range

Now: $122.21
Low: $122.21
High: $122.21

50 Day Range

MA: $123.21
Low: $120.98
High: $128.51

2 Week Range

Now: $122.21
Low: $28.39
High: $132.54

Volume

N/A

Average Volume

128,113 shs

Market Capitalization

$4.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
America’s worst nightmare?
From Porter & Company   |   Ad
What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.
Click here to watch this bombshell exposé now.